Roche · company speakers →
recapped preclinical efforts involving RO7567132, a bispecific antibody designed to target FAP and lymphotoxin beta receptor (LTBR), which is expressed on a variety of cells in the microenvironment and the vasculature, and sensitize tumors to immunotherapy.
Is this you? Claim this profile →
No public contact links on file.
Sourcing speakers for your event?
Browse the speaker directory →